Drugs against Marek's disease virus and application of resveratrol or chlorogenic acid and their combined use in drug preparation
Resveratrol and chlorogenic acid are inhibitors of MDV049 protease, which has solved the problem that existing vaccines cannot prevent MDV replication, effectively inhibit MDV replication and tumor generation in chickens, and enhanced the vaccine defense effect. And lower the dosage used.
Patent Information
- Application Number
- CN202410247447.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-05
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-03-05
AI Technical Summary
The existing Marek's disease virus (MDV) vaccine cannot prevent the virus from replication and increased virility in chickens, causing vaccine-immunized chickens to become new sources of infection and promote the emergence of more virulent strains, which lacks Drugs that effectively inhibit MDV replication.
Resveratrol and chlorogenic acid were used alone or in combination as MDV049 protease inhibitors, which significantly reduce viral replication by inhibiting MDV049 protease activity and effectively inhibit the replication and tumorigenesis of MDV in chicken cells under safe dosage.
Resveratrol and chlorogenic acid can significantly inhibit the replication and tumorigenesis of MDV in cellular and animal models, enhance vaccine defense effects, prevent MDV virility enhancement, and use doses lower than conventional doses, which have good economic value and research. significance.
Smart Images

Figure CN118021772B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the application field of natural compounds, and in particular to the application of natural compounds resveratrol and chlorogenic acid alone or in combination as drugs for inhibiting the replication of Marek's disease virus and resisting the occurrence of Marek's disease. Background Art
[0002] Chickens infected with the pathogenic serotype I Marek's disease virus (MDV) will cause Marek's disease (MD), which is a highly lethal viral infectious disease with multiple visceral tumors. Chickens are the most important natural host of MDV. MDV belongs to the cell-bound herpesvirus family, and its molecular structure and genetic composition are similar to those of alpha herpesviruses.
[0003] At present, the main means of defending against MD is to vaccinate against MD. Studies have shown that vaccination against MD can protect chickens from developing MD malignant tumors, but chickens immunized with MD vaccines can still be infected with MDV, and MD vaccines cannot prevent the replication, maturation, and release of MDV in chickens. Therefore, chickens immunized with MD vaccines become new sources of infection for MDV, and the immune pressure of the vaccine further promotes the continuous enhancement of MDV virulence, resulting in the emergence of more virulent MDV strains. Therefore, MDV is still an important threat to the poultry industry. However, preventing MDV from replicating in chicken cells is an effective way to curb the proliferation, spread, and virulence enhancement of MDV, and is also the key to controlling MD outbreaks and enhancing the defensive effect of vaccines.
[0004] Resveratrol has a CAS number of 501-36-0 and its English name is Resveratrol (trans-Resveratrol; SRT501). It is a natural polyphenol with a molecular formula of C 14 H 12 O3, with a relative molecular mass of 228.24. It has antioxidant, anti-inflammatory, cardioprotective and anti-cancer properties. It can inhibit mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, and DNA polymerase. Resveratrol is a specific activator of SIRT1, an effective inhibitor of pregnane X receptor (PXR), and an Nrf2 activator. It can improve aging-related progressive renal damage in mouse models. Resveratrol acts on endothelial cells to promote NO production. Resveratrol plays a role in various cell life processes, but there has been no report on resveratrol's anti-Marek's disease or any inhibition of MDV virus replication and activity.
[0005] Other Chinese names for chlorogenic acid include green acid, coffee tannic acid, coffee tannic acid, 5-caffeoylquinic acid, etc. Its English name is Chlorogenic acid, its CAS number is 327-97-9, and its molecular formula is C 16 H 18O9, molecular weight is 354.31. Chlorogenic acid is mainly found in fruits, vegetables and plants of the genus Lonicera of the family Caprifoliaceae and the genus Kobus of the family Asteraceae. It is a phenylpropanoid compound produced by the plant body through the shikimic acid pathway during aerobic respiration. It is a derivative of caffeoylquinic acid with strong antioxidant capacity. It also has the functions of anti-HIV, anti-tumor cells, antibacterial, improving central excitement, choleretic, lowering blood lipids, enhancing adrenaline, anti-teratogenic, anti-allergic and regulating cytochrome P450 enzyme activity. Chlorogenic acid plays a role in various life processes of various cells, but there has been no report on chlorogenic acid's anti-Marek's disease or any inhibition of MDV virus replication and activity. Summary of the invention
[0006] In order to resist the occurrence of chicken MD, inhibit the replication of MDV in chicken cells, improve the defense effect of MD vaccine, and curb the enhancement of MDV virulence, the present invention provides a new use of resveratrol and chlorogenic acid alone or in combination as drugs for inhibiting MDV replication and resisting Marek's disease in chickens. Based on the MDV049 protease activity inhibition system encoded by MDV, as well as cell inoculation virus and Marek's disease animal models, it is screened that resveratrol and chlorogenic acid alone or in combination can effectively inhibit the replication of MDV and the generation of tumors in virus-challenging experimental animal models at safe dosages.
[0007] Unless otherwise specified, the drugs and reagents involved in the present invention are all mixtures of commercial reagents or artificially synthesized reagents. The preparation or extraction methods of the artificial synthesis are existing technologies and are not the subject of protection of the present invention.
[0008] The present invention provides a drug for inhibiting Marek's disease virus, comprising an MDV049 protease inhibitor, wherein the MDV049 protease inhibitor comprises at least one of resveratrol or chlorogenic acid.
[0009] The present invention provides a drug for inhibiting MDV replication, including resveratrol and chlorogenic acid used alone or in combination. The resveratrol and chlorogenic acid of the present invention used alone or in combination have the effect of resisting MDV and MD.
[0010] The present invention provides a drug for preventing or resisting Marek's disease, including the drug for inhibiting MDV replication.
[0011] Resveratrol and chlorogenic acid inhibit the activity of MDV049 protease encoded by MDV, and the function of MDV049 protein has not been explained in detail. The present invention performs high-throughput screening on more than 3,800 compounds, and fortunately finds that the resveratrol and chlorogenic acid have the effect of inhibiting the activity of MDV049 protease. Through the research of the present invention, the resveratrol and chlorogenic acid achieve the inhibition of MDV replication at the cellular level by inhibiting MDV049 protease, and have no significant inhibitory effect on the signaling pathways and proteins of chicken cells themselves.
[0012] Resveratrol and chlorogenic acid, as protease inhibitors, can affect the functions of multiple signal pathways and proteins in cells. The research of the present invention shows that resveratrol and chlorogenic acid specifically inhibit the activity of MDV049 protease.
[0013] Preferably, the resveratrol and / or chlorogenic acid are used to inhibit the replication of Marek's disease virus in in vitro cultured cells; in in vitro cell culture, the resveratrol has an effective concentration of 0.1 to 200 μM at the cell level; or the chlorogenic acid has an effective concentration of 1.2 to 300 μM at the cell level; or 0.1 to 200 μM resveratrol and 1.2 to 300 μM chlorogenic acid are used in combination at the cell level. Preferably, within this combined drug concentration range, the molar concentration ratio of resveratrol to chlorogenic acid can synergistically inhibit MDV replication under the conditions of 2:1-1:8, and further preferably, the inhibitory effect is best under the combined drug condition of 1:2. Preferably, within this combined drug concentration range, the molar concentration ratio of resveratrol to chlorogenic acid is 2:1, 1:1, 1:4, 1:8.
[0014] The preferred cells at the cell level are CEF cells or DF-1 cells. Preferably, the concentration of resveratrol at the cell level is preferably 0.1 to 200 μM, and further preferably, 0.1 μM resveratrol inhibits the replication of MDV at the CEF cell level. Preferably, 0.1 μM, 1 μM, 5 μM, 10 μM, 50 μM, 80 μM, 150 μM, 200 μM and resveratrol in the range therebetween effectively inhibit the replication of MDV in cells infected with MDV, while having no toxic side effects on the cells themselves. When the concentration of resveratrol is greater than 0.1 μM, the replication of the virus can be significantly reduced. When the concentration reaches 4 μM, the replication of the virus in the cell and the infection of the cell can be basically completely inhibited, and the drug does not cause significant damage to the cell in this concentration range. Preferably, the concentration of chlorogenic acid at the cell level is preferably 1.2 to 300 μM. It is further preferred that 1.2 μM chlorogenic acid inhibits the replication of MDV at the CEF cell level. Preferably, 1.2 μM, 2 μM, 5 μM, 10 μM, 20 μM, 50 μM, 80 μM, 150 μM, 200 μM, 250 μM, 300 μM and chlorogenic acid in the range therebetween effectively inhibit the replication of MDV in cells infected with MDV, while having no toxic side effects on the cells themselves. When the concentration of chlorogenic acid is greater than 1.2 μM, the replication of the virus can be significantly reduced. When the concentration reaches 8 μM, the replication of the virus in the cell and the infection of the cell can be basically completely inhibited, and the drug does not cause significant damage to the cell in this concentration range. It is further preferred that at the cell level, the combination of the above-mentioned preferred concentrations of resveratrol and chlorogenic acid inhibits the replication of the virus in the cell and the infection of the cell.
[0015] The resveratrol and chlorogenic acid inhibit the replication of MDV in cells. By adding the resveratrol and chlorogenic acid alone or in combination to the culture system of chicken cells infected with MDV, the replication of MDV is significantly inhibited. Preferably, the resveratrol and chlorogenic acid inhibit the replication of the virus at the level of CEF cells (chicken embryo fibroblasts) or DF-1 cells (chicken embryo fibroblast cell line) infected with MDV.
[0016] Preferably, any of the above items is that the MDV is serotype I MDV.
[0017] Any of the above items is preferably that the resveratrol and / or chlorogenic acid is used to inhibit the replication of Marek's disease virus in cells in vivo or to inhibit the formation of Marek's disease tumors in chickens caused by Marek's disease virus; the dosage of the drug used in animals is 0.2-260 mg / (kg·d) of resveratrol; or 1-600 mg / (kg·d) of chlorogenic acid; or 0.2-260 mg / (kg·d) of resveratrol and 1-600 mg / (kg·d) of chlorogenic acid in combination. Preferably, within the combined dosage range, the ratio of resveratrol to chlorogenic acid can play a synergistic role in inhibiting the replication of MDV and anti-MD in animals under the conditions of 2:1-1:8, and further preferably, the inhibition effect is best under the combined dosage condition of 1:2. Preferably, within the combined dosage range, the ratio of resveratrol to chlorogenic acid is 2:1, 1:1, 1:4, 1:8.
[0018] Preferably, any of the above items is that the administration method includes at least one of oral administration, intraperitoneal injection or intramuscular injection.
[0019] Preferably, any of the above items, when orally administered, is orally administered according to any one of the following dosages ① to ③: ① resveratrol at a dosage of 40 to 230 mg / (kg·d), ② chlorogenic acid at a dosage of 12 to 600 mg / (kg·d), ③ a combination of 40 to 230 mg / (kg·d) of resveratrol and 12 to 600 mg / (kg·d) of chlorogenic acid.
[0020] Preferably, any of the above items is administered by intraperitoneal injection according to any one of the following doses ④ to ⑥: ④ resveratrol at a dose of 0.2 to 140 mg / (kg·d); ⑤ chlorogenic acid at a dose of 1 to 400 mg / (kg·d); ⑥ a combination of 0.2 to 140 mg / (kg·d) resveratrol and 1 to 400 mg / (kg·d) chlorogenic acid.
[0021] Preferably, any of the above items, when injected intramuscularly, is administered intramuscularly according to any one of the following doses ⑦ to ⑨: ⑦ a dose of resveratrol of 10 to 260 mg / (kg·d); ⑧ a dose of chlorogenic acid of 7 to 500 mg / (kg·d); ⑨ a combination of 10 to 260 mg / (kg·d) of resveratrol and 7 to 500 mg / (kg·d) of chlorogenic acid.
[0022] Any of the above items is preferably a drug for preventing or resisting Marek's disease provided by the present invention, wherein the resveratrol and chlorogenic acid are used alone or in combination, and the dosage of resveratrol in animals is 0.2-260 mg / (kg·d), and the dosage of chlorogenic acid in animals is 1-600 mg / (kg·d). The dosage used in animals is the dosage used in chickens. The resveratrol and chlorogenic acid are used as MDV049 protease inhibitors. The present invention first discovered that the resveratrol and chlorogenic acid inhibit the activity of MDV049 protease in the Marek's disease animal model, but have no inhibitory effect on the protease in the chicken itself, and resveratrol and chlorogenic acid have no toxic side effects on chickens. The dosage can inhibit the activity of MDV049 protease, significantly inhibit the occurrence of symptoms such as internal bleeding and tumors in chickens infected with MDV, and inhibit the replication of MDV in chicken T cells, that is, inhibit the occurrence of Marek's disease in chickens.
[0023] Any of the above items is preferably that the dosage of resveratrol in animals is not less than 0.2 mg / (kg·d), and the dosage of chlorogenic acid in animals is not less than 1 mg / (kg·d). When the dosage of resveratrol is greater than 0.2 mg / (kg·d), and the dosage of chlorogenic acid is greater than 1 mg / (kg·d), either alone or in combination, the occurrence of symptoms such as internal bleeding and tumors in chickens infected with MDV can be significantly inhibited, and the replication of MDV in chicken T cells can be inhibited, that is, resveratrol and chlorogenic acid can inhibit the occurrence of Marek's disease in chickens.
[0024] Any of the above items is preferably that the resveratrol, when taken orally, has a dosage of 40 to 230 mg / (kg·d), preferably, the best oral dosage of resveratrol is 110 mg / (kg·d), and other preferred oral dosages of resveratrol are 40, 60, 80, 100, 150, 170, 200, 220, 230 mg / (kg·d); when intraperitoneally injected, the dosage of resveratrol is 0.2 to 140 mg / (kg·d), preferably, the best intraperitoneal injection dosage of resveratrol is 50 mg / (kg·d), Other preferred intraperitoneal injection doses of resveratrol are 0.2, 0.5, 1.0, 2.0, 5.0, 10, 25, 50, 100, and 140 mg / (kg·d); when injected intramuscularly, the dose of resveratrol is 10 to 260 mg / (kg·d). Preferably, the best intramuscular injection dose of resveratrol is 86 mg / (kg·d). Other preferred intramuscular injection doses of resveratrol are 10, 19, 26, 38, 42, 72, 97, 113, 144, 184, 209, 220, and 260 mg / (kg·d).
[0025] Any of the above items is preferably that the chlorogenic acid, when taken orally, has a chlorogenic acid dosage of 12 to 600 mg / (kg·d), preferably, the best oral dosage of chlorogenic acid is 150 mg / (kg·d), and other preferred oral dosages of chlorogenic acid are 12, 20, 30, 40, 60, 80, 100, 200, 250, 300, 350, 400, 600 mg / (kg·d); when intraperitoneally injected, the chlorogenic acid dosage is 1 to 400 mg / (kg·d), preferably, the best intraperitoneal injection dosage of chlorogenic acid is 80 mg / (kg·d), and the His preferred intraperitoneal dose of chlorogenic acid is 1, 3, 5, 10, 20, 40, 60, 80, 100, 150, 200, 250, 300, 400 mg / (kg·d); when injected intramuscularly, the dose of chlorogenic acid is 7 to 500 mg / (kg·d). Preferably, the best intramuscular dose of chlorogenic acid is 100 mg / (kg·d). Other preferred intramuscular doses of chlorogenic acid are 7, 14, 25, 35, 50, 60, 80, 100, 150, 200, 250, 300, 400, 500 mg / (kg·d).
[0026] Preferably, any of the above items is a combination of resveratrol and chlorogenic acid within the dosage range of any of the above items.
[0027] Preferably, any of the above items is that the resveratrol and chlorogenic acid, used alone or in combination within the dosage range described in any of the above items, inhibit the formation of MD tumors in chickens infected with MDV.
[0028] The present invention also provides the use of resveratrol or chlorogenic acid in the preparation of MDV049 protease inhibitor.
[0029] The present invention also provides the use of resveratrol or chlorogenic acid or the combination of resveratrol and chlorogenic acid in the preparation of a drug for preventing or treating Marek's disease.
[0030] The present invention also provides the use of resveratrol or chlorogenic acid or the combination of resveratrol and chlorogenic acid in the preparation of a drug for inhibiting tumor formation in Marek's disease chickens or the preparation of a drug for inhibiting the replication of Marek's disease virus.
[0031] The beneficial effect of the present invention is that the present invention screens out for the first time the single and combined use of resveratrol and chlorogenic acid, which can not only inhibit the activity of MDV049 protease at the enzyme level and the replication of MDV at the cell level, but also inhibit the growth of MD tumors and visceral bleeding at the animal level, and inhibit the replication of MDV in virus-infected chickens, and has a very strong effect. Preferably, the dosage of resveratrol and chlorogenic acid used as MDV049 protease inhibitors and the dosage used in the combined use in the present invention are much lower than the effective dosage of resveratrol and chlorogenic acid in conventional use, and have the advantage of small dosage, and can be widely used as anti-MD drugs in the production practice of poultry industry to defend against MD, and have good economic value and research significance. The conventional dose refers to the dose of resveratrol and chlorogenic acid in other medicinal applications in the prior art, such as 600 mg / kg for oral administration of resveratrol to chickens for antioxidant effects, and 400 mg / kg for oral administration of chlorogenic acid to chickens for anti-Cd poisoning effects. The dose of resveratrol and chlorogenic acid used as MDV049 protease inhibitors, or the dose for inhibiting tumor formation in Marek's disease-stricken chickens, or the dose for inhibiting Marek's disease virus replication, or the dose for preventing or treating Marek's disease are significantly lower than the minimum effective doses for other animals and other applications reported in the prior art.
[0032] At present, the virulence of MDV is constantly increasing, and chickens vaccinated with the vaccine may still suffer from Marek's disease. Under this situation, the present invention has found a new way to control Marek's disease, and can enhance the effect of MD vaccine, and has a wide application prospect. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 This is the result of resveratrol and / or chlorogenic acid inhibiting the activity of MDV049 protease encoded by MDV according to the preferred embodiment 1 of the present invention.
[0034] Figure 2 These are the results of the cytotoxicity of resveratrol and chlorogenic acid alone or in combination on CEF cells according to the preferred embodiment 2 of the present invention.
[0035] Figure 3 This is a diagram of cytopathic effect (CPE) after three days of treatment with MDV or MDV+drug according to Example 2 of the present invention.
[0036] Figure 4 This is a relationship diagram of the CPE area of resveratrol, chlorogenic acid alone and in combination with MDV in Experimental Example 2 of the present invention.
[0037] Figure 5 This is a graph showing the relationship between the MDV genome copy number in CEF cells of Example 2 of the present invention and the single-drug and combined-drug use of resveratrol and chlorogenic acid.
[0038] Figure 6 This is a graph showing the relationship between the MDV genome copy number in the MD model chicken T cells of Example 3 of the present invention and the single and combined use of resveratrol and chlorogenic acid.
[0039] Figure 7 This is a relationship diagram between the incidence of MD in MD model chickens in Example 3 of the present invention and the use of resveratrol and chlorogenic acid alone or in combination.
[0040] Figure 8 This is a schematic diagram of the relationship between the single medication and combined medication of resveratrol and chlorogenic acid in Example 3 of the present invention and the number of tumors in MD model chickens. DETAILED DESCRIPTION
[0041] The present invention is described more clearly and completely through the following examples, but the examples described are only part of the embodiments of the present invention, not all of them. The embodiments are to help understand the present invention and should not be used to limit the scope of protection of the present invention.
[0042] Example 1
[0043] Resveratrol and chlorogenic acid inhibit the activity of MDV049 protease encoded by MDV.
[0044] Enzyme reaction system: A 100 μL reaction system contains 2.5 nM MDV049 protease (Genbank#AAG14229.1, preparation and activity analysis methods refer to: Wang Mengyun (mentor: Ai Yongxing). Activity and enzymatic specificity analysis of MDV-encoded deubiquitinase UL36 (Thesis) (2017).), 1× reaction buffer (50 mM HEPES pH7.8, 0.1 mg / mL BSA, 0.5 mM EDTA, 1 mM DTT), 70 nM fluorescent substrate Ub-Rho110 is added to the reaction, incubated at 37°C, and the fluorescence intensity change is measured on a fluorescence spectrophotometer to obtain the initial reaction rate. The reaction system with different concentrations of resveratrol and chlorogenic acid added alone or in combination was used as the inhibitor group, and the reaction system without drugs but with an equal amount of PBS added was used as the "control group". The results are as follows Figure 1 In the "control group", MDV049 protease hydrolyzed Ub-Rho110 normally, while the activity of MDV049 in each inhibitor group was inhibited, and combined use of drugs produced a stronger inhibitory effect. This result shows that resveratrol and chlorogenic acid alone or in combination inhibited the enzymatic activity of MDV049 encoded by MDV.
[0045] Example 2
[0046] Preparation of CEF cells and infection with MDV:
[0047] 1. Take a 10-day-old SPF chicken embryo and wipe it with alcohol cotton, starting from the air chamber and wiping around to disinfect. Then put the chicken embryo into the clean bench with the air chamber facing upwards. Carefully use autoclaved tweezers to break the air chamber and remove the eggshell.
[0048] 2. Use new sterile tweezers to peel off the chorioallantoic membrane, discard the egg shell and vitelline membrane. Use sterile tweezers to clamp the head of the chicken embryo and gently move it to the plate.
[0049] 3. Fix the head with sterile tweezers, cut off the head, limbs, and organs with sterile scissors, and rinse repeatedly with sterile PBS until colorless.
[0050] 4. Use sterile scissors to cut the tissue blocks into small pieces until there are no large particles of tissue, add 8 mL of sterile PBS to wash, let it stand for 1 minute, and use a pipette to discard the suspension mixed with red blood cells and tissue fragments.
[0051] 5. Add 0.25% trypsin at 3 to 5 times the volume of the tissue block, place it in a 37°C water bath for digestion for 15 minutes, and shake it continuously during the digestion. When the tissue turns white and loose, add FBS with a final concentration of 10% to terminate the digestion, and repeatedly blow the cells to disperse them into single cells.
[0052] 6. After filtering the cell suspension with sterile gauze, add the filtrate into a centrifuge tube, centrifuge at 1000r / min at room temperature for 8 minutes, and discard the supernatant.
[0053] 7. Resuspend the cells in DMEM medium containing 10% FBS, dilute to an appropriate concentration, add to the cell culture flask, and culture in a 37°C, 5% CO2 incubator until the cells grow into a monolayer of cells and reach 80% abundance.
[0054] 8. Remove the virus from liquid nitrogen and dilute it with culture medium.
[0055] 9. Add the virus to the monolayer of CEF cells.
[0056] CCK-8 assay to detect the cytotoxicity of resveratrol or chlorogenic acid on CEF:
[0057] 1. Treatment of CEF cells with resveratrol or chlorogenic acid: 20,000 CEF cells were plated in each well of a 96-well plate, resveratrol or chlorogenic acid was diluted into a concentration gradient with culture medium, and the culture medium containing the resveratrol concentration gradient was added to the 96-well plate, with a volume of 100 μL per well, and cultured in a 37°C, 5% CO2 incubator for 72 h.
[0058] 2. CCK-8 method was used to detect cell viability. The specific operation was as follows: 10 μL CCK-8 solution was added to each well of the above 96-well plate, and then the culture plate was placed in a 37°C, 5% CO2 incubator for incubation for 3 hours. The absorbance value (OD value) at a wavelength of 450nm was measured with an enzyme marker, and the OD value of each parallel well was averaged. Cell viability % = (OD450 of drug-treated cells-blank OD450) / (OD450 of control cells-blank OD450) × 100%, and the experiment was repeated three times. The safe concentration of resveratrol or chlorogenic acid for CEF cells was determined to be no less than 95% of the group without drug treatment. The results are as follows Figure 2 , the cell viability of 220μM resveratrol and 320μM chlorogenic acid treated alone was above 95%, but when used in combination at this concentration, the cell viability was less than 95%, while the cell viability of 200μM resveratrol and 300μM chlorogenic acid was above 95% whether used alone or in combination. Therefore, the safe concentration of resveratrol for CEF cells is <200μM, and the safe concentration of chlorogenic acid for CEF cells is <300μM.
[0059] Resveratrol and chlorogenic acid inhibit MDV replication alone or in combination at the CEF cell level:
[0060] 1. Morphological observation: 200,000 cells were plated in each well of a 6-well plate. After the cells adhered to the wall and grew into a monolayer, the culture medium was replaced with a culture medium containing an equal volume of DMSO, 2.5 μM resveratrol, or 5 μM chlorogenic acid, respectively or together, and 200 PFU of resveratrol was inoculated into each well. After three days, the CPE caused by MDV was observed under a microscope. Figure 3 As shown, the CPE area was recorded and graphed using Graph Pad Prism 10, with the abscissa being the drug concentration and the ordinate being the CPE area, as shown Figure 4 As shown, the experiment was repeated three times. The results showed that compared with the control group, the CPE area on CEF cells was significantly reduced by resveratrol and chlorogenic acid alone or in combination (the resveratrol group decreased by 68.99%, the chlorogenic acid group decreased by 68.43%, and the combined treatment decreased by 94.39%). The software CompuSyn (v1.0.1) was used to analyze the Combination Index (CI), and it was found that under the condition of a molar concentration ratio of resveratrol: chlorogenic acid = 1:2, the combined treatment had the best effect, which was better than the single treatment, and was a synergistic effect (CI <0.4). This shows that resveratrol and chlorogenic acid alone or in combination can inhibit the formation of MDV-induced CEF cell lesions, and the combined treatment effect is better than the single treatment.
[0061] 2. Copy number changes
[0062] a. Drawing of standard curve
[0063] According to the MDV049 gene sequence in the MDV genome (GenBank#AF243438.1), a fluorescence quantitative PCR standard plasmid pM18T-MDV049 (500) (containing the nucleic acid sequence of the N-terminal 500 amino acids of the MDV049 gene coding sequence) was constructed, and a pair of real-time fluorescence quantitative PCR primers were designed based on the standard plasmid sequence, the upstream primer is shown in Seq ID NO: 1, and the downstream primer is shown in Seq ID NO: 2. By performing Q-PCR on the standard plasmid, a standard curve with a good linear relationship was drawn using the CT value and the standard plasmid copy number, and the experiment was repeated three times.
[0064] b. Determination of viral copy number
[0065] 200,000 cells were plated in each well of a 6-well plate. After the cells adhered to the wall and grew into a monolayer, the culture medium was replaced with a culture medium containing an equal volume of DMSO, 2.5 μM resveratrol, or 5 μM chlorogenic acid, either alone or together, and 200 PFU were inoculated in each well. The genome was extracted from each well. Q-PCR was performed using the above primers. Quantitative analysis was performed based on the results. The CT values obtained for each group were substituted into the standard curve to obtain the copy number. Graph Pad Prism 10 was used to draw a graph. The horizontal axis is the drug concentration, and the vertical axis is the copy number, as shown in Figure 1. Figure 5 As shown. The experiment was repeated three times. The results showed that compared with the control group, the number of MDV copies in CEF cells was significantly reduced by resveratrol and chlorogenic acid alone or in combination (resveratrol decreased by 52.36%, chlorogenic acid decreased by 54.29%, and combined use decreased by 89.07%). This shows that resveratrol and chlorogenic acid alone or in combination can inhibit the replication of MDV in CEF cells, and the combined use is better than the single use.
[0066] c. Evaluation of combined medication
[0067] The above CPE area and MDV copy number changes corresponded to the corresponding single and combined drug concentrations. The software CompuSyn (v1.0.1) was used to analyze the Combination Index (CI). It was found that when the molar concentration ratio of resveratrol: chlorogenic acid was 1:2, the combined drug effect was the best, and the effect was better than that of single drug use, which was a synergistic inhibitory effect (CI = 0.316).
[0068] Example 3
[0069] Resveratrol and chlorogenic acid alone or in combination inhibited MDV replication and the occurrence of MD in the chicken MD disease model:
[0070] The specific operation is as follows: 1-day-old SPF chickens were taken, and the MDV titer was 200 PFU. The challenge method was intraperitoneal inoculation. These challenged chickens were given intraperitoneal injections of resveratrol, chlorogenic acid alone and in combination every day. The experimental group was given an effective dose of the drug (Table 1), and the group that was not treated with the drug and only injected with an equal amount of saline was used as the control group. There were 5 chickens in each group. Blood was collected from the blood vessels under the wings 20 days after the challenge, and T lymphocytes were isolated. The MDV gene copy number was quantitatively analyzed based on the number of 200,000 cells, such as Figure 6 The incidence of MD in each group of chickens within 50 days after infection was calculated. Figure 7 . Fifty days after infection or when the animals were close to death during this period, autopsies were performed and the number of visceral tumors was recorded, with the number of tumors in the liver and spleen being counted and plotted. Figure 8 . Compared with the control group, the incidence of MD in MDV-challenged chickens in each drug group decreased significantly, and the decrease in the combined drug group was more significant (the resveratrol group decreased by 34.34%, the chlorogenic acid group decreased by 35.35%, and the combined drug group decreased by 88.89%); the number of MDV genome copies in T cells decreased significantly (the resveratrol group decreased by 42.50%, the chlorogenic acid group decreased by 40.00%, and the combined drug group decreased by 90.00%); the number of visceral tumors decreased significantly (the resveratrol group decreased by 52.81%, the chlorogenic acid group decreased by 48.31%, and the combined drug group decreased by 87.64%). This shows that resveratrol and chlorogenic acid alone or in combination can inhibit the replication of MDV in chickens and inhibit the occurrence of MD in chickens.
[0071] Example 4
[0072] Resveratrol and chlorogenic acid were used alone or in combination by oral, intraperitoneal and intramuscular injection in the chicken MD disease model. In the effective range of medication in Table 1, the experiment showed that the three administration methods can effectively inhibit the replication of MDV in chickens and inhibit the occurrence of chicken MD. In the same dosage range as the single medication, resveratrol and chlorogenic acid were combined in different proportions for anti-MDV and MD effect analysis. The software CompuSyn (v1.0.1) was used to analyze the combination index (CI). It was found that under the condition of the dosage ratio of resveratrol: chlorogenic acid = 1:2, the combination effect was the best, and the effect was better than the single medication, which was a synergistic effect (CI <0.6). Table 1 shows the safety range, effective range and optimal dose of resveratrol and chlorogenic acid alone and in combination in the three administration methods and cell level experiments. Table 2 shows the three administration methods and the effects of combined medication.
[0073]
[0074] Table 1:
[0075] Table 2:
[0076]
[0077]
[0078] Example 5
[0079] Example 5 The CI analysis was used to compare the effects of single medication or the synergistic effects of combined medication. The CI value calculation and analysis showed (Table 3) that within the effective range of resveratrol and chlorogenic acid, the best CPE inhibition effect was achieved when the molar concentration ratio of resveratrol to chlorogenic acid at the cell level was 1:2, and the best anti-MD and MDV replication inhibition effect was achieved when the dosage ratio of resveratrol to chlorogenic acid at the animal level was 1:2.
[0080] Table 3:
[0081]
[0082] Example 6
[0083] Verify the specific inhibitory effect of resveratrol and chlorogenic acid on MDV049 protease. The experiment showed that resveratrol and chlorogenic acid had no inhibitory effect (>114μM) on chicken USP1, USP7, USP8, USP2, USP5, USP10, USP13, USP15, USP16, USP20, USP33, USP18, USP19, USP28, USP37, USP46, USP47, USP51, CYLD, UCH-L1, UCH-L5, OTU1, OTU4, OTU7 and other proteases.
[0084] The experimental method is the same as the MDV049 protease inhibition experiment. Chicken USP1, USP7, USP8 and other enzymes use 1-3nM enzyme concentrations, and inhibitor concentrations >114μM have no significant inhibitory effect on the above enzyme activities.
[0085] References: Experimental methods and identification standards: Chen, J., et al., Selective and cell-active inhibitors of the USP1 / UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem Biol, 2011. 18(11): p. 1390-400.
[0086] Example 7
[0087] The present invention screens MDV049 protease inhibitors.
[0088] We used MedChemExpress's library of more than 3,800 protease inhibitors for high-throughput screening. Among them, human USP1 inhibitors include ML-323 (Cas No.1572414-83-5), PR-619 (Cas No.2645-32-1), SJB3-019A (Catalog No.B1307), Pimozide (Cas No.2062-78-4), GW7647 (Cas No.265129-71-3), Flupenthixol (Cas No.51529-01-2), Trifluoperazine (Cas No.440-17-5), and Rottlerin (Cas No.82-08-6); and USP7 / 8 inhibitors include HBX19818 (Cas No.1426944-49-1), P22077 (Cas No.1247819-59-5), and GNE-6640 (Cas No.2009273-67-8), GNE-6776 (Cas No.2009273-71-4), NSC 632839 (Cas No.157654-67-6), BAY 11-7082 (Cas No.19542-67-7), USP7-IN-1 (CasNo.1381291-36-6), C598-0466 (Catalog No.A8740), NSC 632839 (Cas No.157654-67-6), etc. have no inhibitory effect on MDV049 protease (>114μM).
[0089] Example 8
[0090] The optimal doses of resveratrol and chlorogenic acid under various administration methods in Table 1 were used to administer to healthy chickens to prevent Marek's disease. The results showed that resveratrol and chlorogenic acid alone and in combination as preventive drugs for Marek's disease effectively reduced the infection rate of MDV in chickens and the incidence of MD. It also proved that oral administration, intramuscular injection, and intraperitoneal injection are all effective administration methods for prevention.
[0091] The above results can be verified by infecting chickens with MDV after preventive medication, and then detecting the chicken MDV infection rate and MD incidence rate, as well as the virus level in the body.
[0092] In the present invention, resveratrol and chlorogenic acid as inhibitors of MDV049 protease are mainly antiviral in the treatment of Marek's disease, that is, the treatment time for Marek's disease is the stage when the virus is infected but no tumor occurs. The enzymatic activity of MDV049 protease inhibits viral replication and the generation of tumor cells, thereby playing a therapeutic role.
[0093] The above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. Use of resveratrol or chlorogenic acid or a combination of resveratrol and chlorogenic acid in the preparation of a drug for preventing or treating Marek's disease, characterized in that: When chlorogenic acid is used alone, the concentration of the chlorogenic acid is 1.2 to 300 μM.
2. Use of resveratrol or chlorogenic acid or a combination of resveratrol and chlorogenic acid in the preparation of a drug for inhibiting tumor formation in chickens with Marek's disease, characterized in that: When chlorogenic acid is used alone, the concentration of the chlorogenic acid is 1.2 to 300 μM.
3. Use of resveratrol or chlorogenic acid or a combination of resveratrol and chlorogenic acid in the preparation of a drug for inhibiting the replication of Marek's disease virus, characterized in that: When chlorogenic acid is used alone, the concentration of the chlorogenic acid is 1.2 to 300 μM.
